Multidrug resistant lncRNA profile in chemotherapeutic sensitive and resistant ovarian cancer cells

作者：Xu, Juan; Wu, Jiacong; Fu, Chenyang; Teng, Fang; Liu, Siyu; Dai, Chencheng; Shen, Rong; Jia, Xuemei^*

来源：Journal of Cellular Physiology, 2018, 233(6): 5034-5043.

DOI：10.1002/jcp.26369

• cisplatin
• epirubicin
• LncRNA
• multidrug resistance
• ovarian cancer
• paclitaxel

Most ovarian cancer patients are chemosensitive initially, but finally relapse with acquired chemoresistance. Multidrug-resistance is the extremely terrible situation. The mechanism for the acquired chemoresistance of ovarian cancer patients is still not clear. LncRNAs have been recognized as the important regulator of a variety of biological processes, including the multidrug-resistant process. Here, we carried out the lncRNA sequencing of the ovarian cancer cell line A2780 and the paxitaxel resistant cell line A2780/PTX which is also cross resistant to the cisplatin and epirubicin. Through integrating the published data with the cisplatin resistant lncRNAs in ovarian cancer cell line or ovarian cancer patients, 5 up-regulated and 21 down-regulated lncRNAs are considered as the multidrug-resistant lncRNAs. By real-time PCR analysis, we confirmed the 5 up-regulated and 4 down-regulated multidrug resistant lncRNAs were similarly changed in both the multidrug resistant ovarian cancer cell lines and the multidrug resistant colon cancer cell lines. Furthermore, we conducted the lncRNA-mRNA co-expression network to predict the potential multidrug resistant lncRNAs' targets. Interestingly, the multidrug resistant genes ABCB1, ABCB4, ABCC3, and ABCG2 are all co-expressed with lncRNA CTD-2589M5.4. Our results provide the valuable information for the understanding of the lncRNA function in the multidrug resistant process.

• 出版日期2018-6
• 单位南京医科大学